SYNE1 and neoplasm: This included the measurement of CPG2 enzyme levels in serum, tumour and normal tissues, 131I-labelled conjugate biodistribution studies, immunogenicity assessment, prodrug pharmacokinetic analysis and comet assay for DNA interstrand cross-links.